Cayman Atomoxetine (hydrochloride)

Atomoxetine is a selective norepinephrine reuptake inhibitor with K_i values of 5, 77, and 1,451 nM for norepinephrine, serotonin, and dopamine transporters, respectively.¹ It is selective over the choline, GABA, and adenosine transporters, and a number of neurotransmitter receptors, ion channels, second messengers, and brain/gut peptides. In the rat prefrontal cortex (PFC), it increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression. Atomoxetine (0.1, 0.5, and 1 mg/kg) reduces premature responding, a measure of impulsivity, by rats in the 5-choice serial reaction time test (5CSRTT) in a dose-dependent manner.² It also has neuroprotective effects when administered prior to ischemic damage in a gerbil model of transient cerebral ischemia.³ Formulations containing atomoxetine have been used in the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.

WARNING This product is not for human or veterinary use.